395 related articles for article (PubMed ID: 30969136)
1. RATIONALE 301 study: tislelizumab versus sorafenib as first-line treatment for unresectable hepatocellular carcinoma.
Qin S; Finn RS; Kudo M; Meyer T; Vogel A; Ducreux M; Macarulla TM; Tomasello G; Boisserie F; Hou J; Li X; Song J; Zhu AX
Future Oncol; 2019 Jun; 15(16):1811-1822. PubMed ID: 30969136
[TBL] [Abstract][Full Text] [Related]
2. Four-year overall survival update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma.
Sangro B; Chan SL; Kelley RK; Lau G; Kudo M; Sukeepaisarnjaroen W; Yarchoan M; De Toni EN; Furuse J; Kang YK; Galle PR; Rimassa L; Heurgué A; Tam VC; Van Dao T; Thungappa SC; Breder V; Ostapenko Y; Reig M; Makowsky M; Paskow MJ; Gupta C; Kurland JF; Negro A; Abou-Alfa GK;
Ann Oncol; 2024 May; 35(5):448-457. PubMed ID: 38382875
[TBL] [Abstract][Full Text] [Related]
3. Tislelizumab versus sorafenib as first-line treatment for advanced hepatocellular carcinoma in China: a cost-effectiveness analysis.
Zheng Z; Lin Y; Cai H
Front Public Health; 2024; 12():1356244. PubMed ID: 38562257
[TBL] [Abstract][Full Text] [Related]
4. Real-world treatment patterns and outcomes for patients with advanced hepatocellular carcinoma initially treated with PD-1 inhibitors.
Zou H; Ge Y; Chen W; Yao D; Oi Lam Ung C; Lai Y; Hu H
Int Immunopharmacol; 2024 May; 132():111947. PubMed ID: 38552296
[TBL] [Abstract][Full Text] [Related]
5. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma.
Sun R; Moraleda JM; Wei LJ
JAMA Oncol; 2024 May; 10(5):674. PubMed ID: 38483380
[No Abstract] [Full Text] [Related]
6. Quantification of Treatment Effect of Tislelizumab vs Sorafenib for Hepatocellular Carcinoma-Reply.
Qin S
JAMA Oncol; 2024 May; 10(5):674-675. PubMed ID: 38483395
[No Abstract] [Full Text] [Related]
7. Response to PD-1 inhibitor after progression on PD-L1 inhibitor in advanced HCC.
Cerniglia M; Klepadlo M; Sheneman D; Kim SS
BMJ Case Rep; 2022 Aug; 15(8):. PubMed ID: 35961684
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant tislelizumab plus stereotactic body radiotherapy and adjuvant tislelizumab in early-stage resectable hepatocellular carcinoma: the Notable-HCC phase 1b trial.
Li Z; Liu J; Zhang B; Yue J; Shi X; Cui K; Liu Z; Chang Z; Sun Z; Li M; Yang Y; Ma Z; Li L; Zhang C; Sun P; Zhong J; Zhao L
Nat Commun; 2024 Apr; 15(1):3260. PubMed ID: 38627377
[TBL] [Abstract][Full Text] [Related]
9. Prolonged Complete Remission Using Tislelizumab for Hepatocellular Carcinoma After Adjuvant Chemotherapy Failure: A Case Report.
Zhu X; Dong S; Tang J; Xie R; Wu H; Guan J; Hu S
J Hepatocell Carcinoma; 2024; 11():1005-1013. PubMed ID: 38854817
[TBL] [Abstract][Full Text] [Related]
10. Pembrolizumab As Second-Line Therapy in Patients With Advanced Hepatocellular Carcinoma in KEYNOTE-240: A Randomized, Double-Blind, Phase III Trial.
Finn RS; Ryoo BY; Merle P; Kudo M; Bouattour M; Lim HY; Breder V; Edeline J; Chao Y; Ogasawara S; Yau T; Garrido M; Chan SL; Knox J; Daniele B; Ebbinghaus SW; Chen E; Siegel AB; Zhu AX; Cheng AL;
J Clin Oncol; 2020 Jan; 38(3):193-202. PubMed ID: 31790344
[TBL] [Abstract][Full Text] [Related]
11. Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma.
Finn RS; Qin S; Ikeda M; Galle PR; Ducreux M; Kim TY; Kudo M; Breder V; Merle P; Kaseb AO; Li D; Verret W; Xu DZ; Hernandez S; Liu J; Huang C; Mulla S; Wang Y; Lim HY; Zhu AX; Cheng AL;
N Engl J Med; 2020 May; 382(20):1894-1905. PubMed ID: 32402160
[TBL] [Abstract][Full Text] [Related]
12. Camrelizumab in patients with previously treated advanced hepatocellular carcinoma: a multicentre, open-label, parallel-group, randomised, phase 2 trial.
Qin S; Ren Z; Meng Z; Chen Z; Chai X; Xiong J; Bai Y; Yang L; Zhu H; Fang W; Lin X; Chen X; Li E; Wang L; Chen C; Zou J
Lancet Oncol; 2020 Apr; 21(4):571-580. PubMed ID: 32112738
[TBL] [Abstract][Full Text] [Related]
13. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
14. Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors.
Desai J; Deva S; Lee JS; Lin CC; Yen CJ; Chao Y; Keam B; Jameson M; Hou MM; Kang YK; Markman B; Lu CH; Rau KM; Lee KH; Horvath L; Friedlander M; Hill A; Sandhu S; Barlow P; Wu CY; Zhang Y; Liang L; Wu J; Paton V; Millward M
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32540858
[TBL] [Abstract][Full Text] [Related]
15. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Finn RS; Ikeda M; Zhu AX; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Mody K; Llovet JM
J Clin Oncol; 2020 Sep; 38(26):2960-2970. PubMed ID: 32716739
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study.
Song Y; Gao Q; Zhang H; Fan L; Zhou J; Zou D; Li W; Yang H; Liu T; Wang Q; Lv F; Guo H; Yang L; Elstrom R; Huang J; Novotny W; Wei V; Zhu J
Leukemia; 2020 Feb; 34(2):533-542. PubMed ID: 31520078
[TBL] [Abstract][Full Text] [Related]
17. Tislelizumab Plus Chemotherapy as First-line Treatment for Advanced Esophageal Squamous Cell Carcinoma and Gastric/Gastroesophageal Junction Adenocarcinoma.
Xu J; Bai Y; Xu N; Li E; Wang B; Wang J; Li X; Wang X; Yuan X
Clin Cancer Res; 2020 Sep; 26(17):4542-4550. PubMed ID: 32561664
[TBL] [Abstract][Full Text] [Related]
18. Tislelizumab: First Approval.
Lee A; Keam SJ
Drugs; 2020 Apr; 80(6):617-624. PubMed ID: 32185681
[TBL] [Abstract][Full Text] [Related]
19. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Nivolumab Plus Ipilimumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib: The CheckMate 040 Randomized Clinical Trial.
Yau T; Kang YK; Kim TY; El-Khoueiry AB; Santoro A; Sangro B; Melero I; Kudo M; Hou MM; Matilla A; Tovoli F; Knox JJ; Ruth He A; El-Rayes BF; Acosta-Rivera M; Lim HY; Neely J; Shen Y; Wisniewski T; Anderson J; Hsu C
JAMA Oncol; 2020 Nov; 6(11):e204564. PubMed ID: 33001135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]